Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Files An 8-K Other Events

ME Staff 8-k
-
0

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Files An 8-K Other Events
ITEM 8.01.Other Events.

On March 21, 2018, Amphastar Pharmaceuticals, Inc. (“Amphastar”) issued a press release announcing that the United States Court for the District of Massachusetts entered final judgment in favor of Amphastar in a lawsuit brought by Momenta Pharmaceuticals, Inc. and Sandoz Inc.

A copy of the press release is being filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

ITEM 9.01.Financial Statements and Exhibits.

(d) Exhibits


Amphastar Pharmaceuticals, Inc. Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 amph_Ex99_1 Exhibit 99.1 Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals,…
To view the full exhibit click here

About Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.